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This case is about a 48-year-old woman known with a reduced butyrylcholinesterase activity, who developed prolonged
neuromuscular blockade following the unintentional administration of succinylcholine. We took the opportunity to monitor the
development of neuromuscular function during this period and blood samples were taken for molecular genetic analysis and for
quantitativeandqualitativeanalysissincenotallcausativemutationsarefunctionallycharacterized.Reducedbutyrylcholinesterase
activity is discussed in many aspects. Clinical considerations are suggested concerning genetic counselling.
1.Introduction
Normally 90 percent of intravenously administered succinyl-
choline is hydrolysed in the plasma by butyrylcholinesterase
(BCHe) before it can bind to the alpha subunits of
the nicotinic cholinergic receptor at the neuromuscular
junction. BCHe hydrolyses ester bonds in many agents;
local anaesthetics-like cocaine, procaine, chloroprocaine,
and tetracaine, and also heroine and mivacurium, are
metabolised by BCHE. Decreased activity of BCHe becomes
clinically relevant in patients carrying at least one causative
mutation in the BCHE gene [1]. The BCHE gene has been
identiﬁed on chromosome 3q26 [2]. The mechanism of
decreased BCHe activity can be qualitative or quantitative,
so diﬀerent variants (phenotypes) of BCHe can be distin-
guished. Apart from the wild type (wt), many variants are
known, for instance the atypical (A), silent (S), or ﬂuoride-
resistant (F) variant, as well as the quantitative J-, K- and H-
variants [1].
Following administration of succinylcholine to a patient
with a known abnormal variant of BCHe, the duration of
relaxation of skeletal muscles is predictable. In this case
history the genotype of the patient was not known yet.
After informed consent obtained from the patient we
describe this case history concerning prolonged neuromus-
cular blockade following succinylcholine administration to a
patient with a reduced butyrylcholinesterase activity and the
follow-up investigation.
2.CaseDescription
A 48-year-old woman (weight: 108kg, height-170cm) was
scheduled for a laparoscopic cholecystectomy because of
cholelithiasis. At the preoperative assessment she reported
postoperative apnoea following a Caldwell-Luc procedure
at the ENT-OR in 1981. A prolonged eﬀect of succinyl-
choline had been conﬁrmed by a dibucaine number of
10, written on a crumpled warning card. The patient
herself was absolutely clear about the condition of her
butyrylcholinesterasedeﬁciency.Hermedicalhistoryshowed
an appendectomy, hypertension, and a trigeminal neuralgia
due to repetitive sinus infections. Current medication was
amitriptyline, gabapentin, diclofenac, omeprazole, metopro-
lol, and acetaminophen combined with codeine.
Induction of anaesthesia was carried out with fen-
tanyl and propofol. To facilitate tracheal intubation 100mg2 Case Reports in Medicine
Table 1: Genotype—Phenotype Relation of Butyrylcholinesterase (BCHE).
Nucleotide Exchange Amino Acid Change Phenotype Variants Reference
98A >G Tyr-33-Cys Silent [1]
109C >T Pro-37-Ser Silent [1]
209A >G Asp-70-Gly Atypical [2]
350T >A G Gly-117-Gly+ Silent [3]
355C >T Gln-119-STOP Silent [4]
375A >T Leu-125-Phe Silent [1]
383A >G Tyr-128-Cys Silent [5]
424G >A Val-142-Met H [6]
510T >G Asp-170-Glu Silent [1]
551C >T Ala-184-Val Fluoride-Resistant [7, 8]
592A >G Ser-198-Gly Silent [1]
596C >T Ala-199-Val Silent [9]
601G >A Ala-201-Thr Silent [1]
728C >T Thr-243-Met Fluoride-Resistant [10]
811G >T Glu-271-STOP Silent [1]
1093G >A Gly-365-Arg Silent [11]
1169G >T Gly-390-Val Fluoride-Resistant [10]
1294G >T Glu-432-STOP [7]
1411T >C Trp-471-Arg Silent [1]
1490A >T Glu-497-Val J [12]
1500T >A Tyr-500-STOP Silent [1]
1543C >T Arg-515-Cys Silent [11]
1553A >T Gln-518-Leu Silent [1]
1615G >A Ala-539-Thr K [13]
succinylcholine (0.9mg/kg) had been administered unin-
tentionally. Maintenance was performed with intermittent
dosages of fentanyl, morphine and a continuous infusion of
propofol. The surgical procedure lasted 90minutes and was
done uneventfully.
Monitoring of neuromuscular function was started using
acceleromyography (TOF-Watch SX), by performing inter-
mittently a “train-of-four”. Determination of the supra-
maximal stimulus could not be performed, as deep neuro-
muscular blockade was already induced. Anaesthesia, using
propofol continuously in combination with intermittent
doses of morphine, and neuromuscular monitoring were
continued until recovery of the TOF-ratio above 90%; at
this value it was assumed that the patient could breathe
without help. Recovery of neuromuscular function took
more than seven hours. The ﬁrst twitch was seen 87minutes
after the administration of succinylcholine. The course was
uneventful although the patient was emotional and anxious
postoperatively we were able to regain her trust after several
talks.
After informing this adverse event to the patient and
her partner, she gave permission to take blood samples
for quantitative and qualitative analysis and for molecular
genetic investigation.
The plasma concentration of cholinesterase was 2520U/l
(ref: 4800–12000U/l) and the dibucaine number was 8.
These results are indicative for a homozygous atypical
variant. Because of the very long clinical duration of action
we did not limit molecular genetic investigations to known
BCHE variants but decided to sequence both strands of
the complete BCHE coding sequence. This identiﬁed a
homozygous A- as well as a homozygous K-variant. The A-
variant (209A > T, leading to Asp70Val) is most causative for
the clinical feature and the K-variant (1615G > A, leading to
Ala539Thr) contributed to the markedly prolonged muscle
relaxation and the dibucaine number of 8. The clinical
signiﬁcance of the K-variant as a single mutation has been
described by G¨ atke et al. [3].
3. Discussion
Immediately after induction, the attending anaesthesiologist
realizedthathehadmadeabigmistakemostprobablycaused
by overconcentration. Although all preparations were done,
in word and writing, this case shows us that anesthesia is
done by humans. Unfortunately man makes mistakes. The
bestthingyoucandoafterwardsistobehonesttothepatient
and that you will try to avoid it in the future.
Succinylcholine in a dosage of 1mg/kg has a rapid onset
(30–60sec.) and a short duration of action (3–5min.). It
mimics the action of acetylcholine at the neuromuscular
junction by depolarising the postjunctional membrane,
provided that the depolarisation is sustained until succinyl-
choline is hydrolysed by BCHe.
BCHe is synthesised by the liver, and among other
plasma cholinesterases its physiological function is stillCase Reports in Medicine 3
not fully understood. In 1957, Werner Kalow identiﬁed
plasma cholinesterase (pseudocholinesterase) as the cause of
variable metabolism of drugs when he described persisting
neuromuscular blockade (apnoea) after the administration
of succinylcholine [4]. By investigating not only the plasma
from susceptible patients but also from their parents, he
discovered a genetic variant of BCHe. By this, he is one of
the founder researchers of pharmacogenetics.
Genetic variants of butyrylcholinesterase result in diﬀer-
encesinclinicalresponsetosuccinylcholine.Thisoftenunex-
pected drug eﬀect with potential morbidity as a consequence
makes decreased BCHe activity a pharmacogenetic disorder
[1]. The activity of the BCHe variants is expressed by a
dibucaine number; the normal enzyme (usual variant: U)
shows a dibucaine number of 70 (70% of its activity can be
inhibited by dibucaine). The most often occurring abnormal
enzyme is called the A-variant (atypical variant) which has
a dibucaine number of 30 or less. Its prevalence is not rare
since the allelic frequency of this A-variant is about 0.02,
leading to an incidence of homozygotes (with a dibucaine
number of 30 or less and a markedly clinical response) of
1 in 2500. Manifestation of the disorder presents during
general anaesthesia where succinylcholine or mivacurium is
used. The normal duration of neuromuscular blockade after
administration of these agents is extended by hours. Cerf
et al. described duration of paralysis ranging from 40 to
720minutes [2]. Duration of neuromuscular blockade can
be further increased by external (nongenetic) factors. These
factors include, for instance, temperature, head- and neck-
related malignancies, high oestrogen levels in parturients at
term, and medication-like depakine or metoclopramide [2].
Patients with an abnormal BCHe activity who are given a
normal dose of succinylcholine undergo a non-depolarizing-
likeblockcharacterizedbyfadeintheresponsetoTOFwhich
is also known as a phase II block.
In response to an adverse event in which an abnormal
BCHe activity is suspected the ﬁrst step is to perform
biochemical investigations to conﬁrm the phenotype [2].
To specify the decreased activity of BCHe molecular genetic
diagnostics are available [5]. Only molecular genetic analyses
are able to distinguish an acquired from an inherited
BCHe deﬁciency [5]. Table 1 shows a summary of identiﬁed
mutations in the BCHE gene, single nucleotide polymor-
phisms leading to phenotypical BCHe activity variants.
DNA analysis in our patient led to the identiﬁcation of
2 homozygous mutations. Linkage between the A- and K-
variants has already been described by Bartels et al.; they
found in 17 out of 19 genes bearing the A- variant also the
K- variant [6].
The A- variant we detected (209A > T, leading to
Asp70Val) is diﬀerent from the most frequent occurring
A variant (209A > T, leading to Asp70Gly). Diagnosing
the mutations in the BCHE gene in our patient, we could
oﬀer family members genetic counselling to screen for this
mutation [7]. To individuals carrying one or more of these
causative mutations it might be advised to wear a medical
alert saying that succinylcholine should not be administered.
Unfortunately this case report shows that it cannot be
guaranteed that succinylcholine will not actually be used.
In conclusion, using neuromuscular blocking agents, it
is recommended to monitor the recovery of neuromuscu-
lar function. Persisting neuromuscular blockade following
the administration of succinylcholine should be investi-
gated using conventional biochemical testing and molecular
genetic testing to distinguish between an inherited or
acquired cause for the decreased activity of BCHe. Applying
this knowledge into clinical practice will improve the safety
of our patients and their relatives.
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